Janux Therapeutics, Inc. (JANX): Total Liabilities
$44.74M
As of 2025-12-31
$79.67M
As of 2026-06-30
+1.1%
3-year compound annual growth
+37.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.74M | +15.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $38.73M | +7.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $36.06M | -16.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $43.27M | +220.6% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $13.50M | +46.2% | 2023-03-10, Balance as of period end |
| 2020-12-31 | $9.23M | n/a | 2022-03-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $44.74M | +15.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $134.59M | +71.4% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $46.33M | -23.0% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $37.28M | -20.8% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.58M | -4.7% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $22.84M | -34.9% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $57.01M | +28.3% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
Compare JANX, ZBIO, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗